Our current partners include both major pharmaceutical and biotechnology companies.

As described in Technology, we believe that for certain clinical indications, IgM and IgA antibodies have several inherent advantages, including:

  • Effective binding to low expression cell surface targets
  • Strong binding to difficult targets, such as carbohydrates and glycosylated antigens
  • Improved cross-linking of cell surface receptors for increased cellular signaling
  • Very potent complement dependent cytotoxicity (CDC)
  • Robust antibody dependent cellular phagocytosis (ADCP)

We convert IgG antibody binding sequences into IgM and IgA antibodies, as we believe that antibodies in those formats will often benefit from these inherent advantages.

We also convert IgG binding sequences into our IgM and IgA based bispecific format, as we believe that in certain clinical applications our asymmetric bispecific antibodies may be more efficacious or safer. Our technology allows us to direct 10 binding units to a low expression or difficult target and one binding unit to an immune effector cell, checkpoint or immuno-stimulant.

In the case of T cell directed killing, our IgM based bispecific technology has demonstrated an enhanced safety profile in terms of cytokine release, as compared to an IgG bispecific.

In addition to inquiries with respect to our pipeline projects, we actively seek additional collaborations to convert IgG or other binding sequences of your interest into monospecific or bispecific IgM or IgA antibodies.

We are also willing to engage in collaborations to discover and create IgM or IgA antibodies against a target of your interest.

If you are interested in discussing the potential of IgM or IgA antibodies or learning more about our technology or pipeline, please contact us at info@igmbio.com.